Defined immune dysregulation and COVID vaccination

Study code
NBR 122

Lead researcher
Christine Parkinson

Study type
Samples and data

Institution or company
Cambridge University Hospitals

Researcher type

Speciality area
Infection, COVID


Currently it is unclear if at risk patient groups respond to COVID-19 vaccination, has adverse risk of toxicity or a blunting of vaccine efficacy. We are in a unique position to assess this as we will collect blood samples from a well defined cohort of subjects with an established  diagnosis of a disease causing single gene defect that will be imminently offered the vaccine. We will compare this with immunotherapy treated patients. We will quantitatively measure adaptive immunity pre- and post- vaccination in these subjects and assess the correlation of this with either vaccine adverse effects or vaccine efficacy.